NHS

Downing Street, London, UK
#ABPI #Association of the British Pharmaceutical Industry #Life sciences #NHS #The King's Fund #UK government

Strong leadership needed for UK life sciences industry success

Health and care researchers at The King’s Fund are calling for the UK government and national NHS leaders to play a greater role in developing guidance and providing leadership of health service partnerships with the life sciences industry.   The UK has a large and thriving life… Read More

#News

Biliary tract
#AstraZeneca #Cancer research #National Institute for Health and Care Excellence (NICE) #NHS #Regulatory

Combination therapy recommended for NHS use for biliary tract cancer 

AstraZeneca has announced that the National Institute for Health and Care Excellence (NICE) has recommended Imfinzi (durvalumab) in combination with gemcitabine and cisplatin (chemotherapy) for NHS use in England and Wales for the first-line treatment of adults with locally advanced, unresectable, or metastatic biliary tract cancer (BTC).1… Read More

#Covid-19 #News

#Healthcare #Life sciences #NHS #Revvity #UK

Revvity opens Scientific Centre of Excellence for genomics

Global health science solutions company Revvity, PerkinElmer’s Life Science and Diagnostics business’ new name and branding, has announced the establishment of a Scientific Centre of Excellence in Cambridge, UK.   Focused on driving genomic insights to accelerate therapeutic discovery, Revvity’s Scientific Centre of… Read More

#News

Patients receiving chemotherapy
#Adverse event #Cancer treatment #Chemotherapy #MHRA #NHS #Unlicensed drug

Patient dies after receiving unlicensed drug

A cancer patient died and three others were hospitalised in the UK after they were administered an unlicensed version of chemotherapy cabazitaxel. According to The Guardian, which reported on the incident, the problem was caused by an issue at private healthcare company Sciensus’… Read More

#News #Trending News

UK
#ABPI #Healthcare #NHS #The King's Fund #UK

UK performs poorly on adoption of new drugs, report shows

The UK spends less on medicines, has a lower adoption of new drugs and poorer health outcomes compared to other similar countries, according to a new report. The King’s Fund report, commissioned by the Association of the British Pharmaceutical Industry (ABPI), gives the UK’s NHS a… Read More

#News

Protesting against health inequalities
#ABPI #Collaboration #Drug discovery #Drug innovation #NHS #Pharma #UK

NHS/industry collaboration could improve access to drugs

Collaborative working between the NHS and industry could reduce variations in uptake of innovative treatments across the UK, a joint report from NHS Confederation and ABPI argues.   Analysis from the report has shown a significant variation in access to innovative medicines for patients across the UK and… Read More

#News

#Drug discovery #Genetic study #Health research programme #Healthcare #NHS #Predictive diagnostics #Public health

How Our Future Health will impact drug discovery 

Recently, DDW reported on how over three million people have been invited to join Our Future Health. Andrew Roddam, CEO of Our Future Health, shares the impact research programmes such as this will have on drug discovery.  Millions of people in the UK and around the world spend many years… Read More

#Exclusive Content #Opinion

Our Future Health study
#Genetic study #Health research programme #NHS #Our Future Health #Predictive diagnostics #UK

Millions invited to join UK’s largest health research programme

Over three million people have been invited to join Our Future Health, which is set to become the UK’s largest ever health research programme. Letters are being sent out this autumn inviting members of the public to join Our Future Health, designed to help develop new ways to prevent, detect… Read More

#News #Trending News